Metaplastic breast cancer is a highly chemoresistant breast cancer subtype with limited therapeutic options. Here, the authors report that the NOS inhibitor, L-NMMA, sensitises metaplastic breast cancer to a selective PI3K inhibitor, alpelisib, and taxane chemotherapy via repression of c-JUN mediated epithelial-to-mesenchymal transition.
- Tejaswini Reddy
- Akshjot Puri
- Jenny Chang
